# Can SS-31 (Elamipretide) protect against hepatic aging and injury?

Canonical source: https://retacompare.com/research/can-ss-31-elamipretide-protect-against-hepatic-aging-and-injury

Peptide Longevity Q&A · 2026-04-30


    Research indicates that SS-31 (Elamipretide) can protect liver function by mitigating ischemia-reperfusion injury through its effects on mitochondrial health, reducing reactive oxygen species, and regulating metabolic pathways. This suggests potential benefits for hepatic aging and overall liver resilience.

 What the research shows

The study published in ACS Nano investigated the protective effects of mitochondria-targeted polydopamine nanoparticles (PPS NPs) modified with the peptide SS-31 in a mouse model of hepatic ischemia-reperfusion injury (IRI). The research aimed to address the lack of clinically approved pharmacological agents for preventing or treating IRI, a condition characterized by excessive mitochondrial reactive oxygen species (ROS) generation that leads to liver dysfunction and complications. The findings demonstrated that SS-31 modification enhanced the mitochondrial-targeting capability of PPS NPs, leading to restored mitochondrial membrane potential and reduced ROS accumulation. Treatment with these nanoparticles significantly alleviated liver injury, decreased inflammatory factors, and inhibited neutrophil recruitment in the IRI model. Additionally, transcriptome sequencing and metabolomics analyses revealed that PPS NPs preserved mitochondrial integrity and regulated metabolic pathways crucial for liver protection.

 Why it matters for longevity

The results of this study are significant in the context of liver health and aging. As the liver plays a critical role in metabolic processes and detoxification, its dysfunction can contribute to various age-related diseases. By focusing on mitochondrial function and oxidative stress, SS-31 (Elamipretide) presents a promising avenue for enhancing liver resilience against age-related decline. The ability to mitigate oxidative damage and inflammation may not only improve liver health but also extend overall healthspan, potentially delaying the onset of age-related liver diseases. This aligns with broader research interests in targeting mitochondrial dysfunction as a strategy to promote longevity and healthy aging.

 Key findings at a glance

SS-31 (Elamipretide) enhances the mitochondrial-targeting capability of polydopamine nanoparticles.

Treatment with PPS NPs significantly mitigates liver injury in a mouse model of ischemia-reperfusion injury.

The peptide helps restore mitochondrial membrane potential and reduce ROS accumulation.

PPS NPs decrease inflammatory factor levels and inhibit neutrophil recruitment.

Transcriptome and metabolomics analyses indicate preservation of mitochondrial integrity and regulation of metabolic pathways.

 How SS-31 (Elamipretide) works (background)

SS-31 (Elamipretide) is a peptide designed to target mitochondria, the energy-producing organelles in cells. By localizing to mitochondria, SS-31 plays a crucial role in restoring mitochondrial function and preventing oxidative stress. In the context of hepatic ischemia-reperfusion injury, the peptide helps maintain mitochondrial membrane potential, which is vital for energy production and cellular health. Additionally, SS-31 reduces the generation of reactive oxygen species, which are harmful byproducts of cellular metabolism that can lead to cell damage and apoptosis. By regulating metabolic pathways, SS-31 contributes to cellular redox homeostasis and suppresses inflammatory responses, making it a potential therapeutic agent for preserving liver function and combating age-related decline.

 Safety, caveats, and what we don't yet know

While the study presents promising findings regarding SS-31 (Elamipretide) and its protective effects against hepatic ischemia-reperfusion injury, it is important to note that the research is preclinical and conducted in animal models. The safety and efficacy of SS-31 in human populations remain to be established through clinical trials. Additionally, the long-term effects and potential side effects of SS-31 treatment are not yet fully understood. Future research should focus on evaluating the peptide's impact on various populations, including those with pre-existing liver conditions or other age-related diseases. Understanding the broader implications of SS-31 on hepatic aging will be crucial for its potential therapeutic application.

 Bottom line

SS-31 (Elamipretide) shows potential in protecting against hepatic aging and injury by enhancing mitochondrial function and reducing oxidative stress. These findings may have implications for liver health and longevity.

 Related questions

 Does SS-31 (Elamipretide) improve mitochondrial function in aging cells?

Research suggests that SS-31 can enhance mitochondrial function by targeting and restoring mitochondrial health, which is crucial for cellular energy production and reducing oxidative stress.

 Can SS-31 (Elamipretide) be beneficial for metabolic disorders?

Given its role in regulating metabolic pathways and reducing inflammation, SS-31 may hold promise for addressing metabolic disorders, although further research is needed to confirm its efficacy in clinical settings.

 What are the potential applications of SS-31 (Elamipretide) in age-related diseases?

SS-31's ability to mitigate oxidative stress and inflammation suggests it could be beneficial in managing various age-related diseases, particularly those affecting liver function and metabolic health.

 Source: PubMed · ACS Nano · published 2026-04-30.

## Sources

- PubMed · ACS Nano: https://pubmed.ncbi.nlm.nih.gov/42057685/